1. Home
  2. WIMI vs KPTI Comparison

WIMI vs KPTI Comparison

Compare WIMI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WiMi Hologram Cloud Inc.

WIMI

WiMi Hologram Cloud Inc.

HOLD

Current Price

$2.38

Market Cap

37.4M

Sector

Technology

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.41

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WIMI
KPTI
Founded
2015
2008
Country
China
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.4M
94.6M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
WIMI
KPTI
Price
$2.38
$7.41
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$22.17
AVG Volume (30 Days)
82.9K
260.1K
Earning Date
12-26-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.43
N/A
Revenue
$61,329,146.00
$142,530,000.00
Revenue This Year
N/A
$3.82
Revenue Next Year
N/A
N/A
P/E Ratio
$1.66
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.24
$3.51
52 Week High
$9.66
$12.45

Technical Indicators

Market Signals
Indicator
WIMI
KPTI
Relative Strength Index (RSI) 27.85 63.93
Support Level $2.70 $7.12
Resistance Level $2.65 $7.52
Average True Range (ATR) 0.18 0.50
MACD -0.03 0.07
Stochastic Oscillator 11.54 80.12

Price Performance

Historical Comparison
WIMI
KPTI

About WIMI WiMi Hologram Cloud Inc.

WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: